Guidelines for Storage
and Preparation


VIVITROL is shipped and should be prepared under specific temperature-controlled conditions to ensure proper delivery and help secure patient safety. Follow these handling instructions for VIVITROL before administering to patients:

  • VIVITROL should always be refrigerated at 2° to 8°C (36° to 46°F) and should not be frozen
  • Store VIVITROL separately from food, in accordance with Occupational Safety and Health Administration Guidelines
  • Unrefrigerated, VIVITROL can be stored at temperatures not exceeding 25°C (77°F) for no more than 7 days prior to administration
  • Do not expose the product to temperatures above 25°C (77°F)
  • The product expiration date is printed on the carton
  • Product received from a pharmacy (specialty or other) is patient-specific
  • Need help identifying specialty pharmacy requirements and other coverage information based on provider state and patient plans? Use the Insurance and Pharmacy Navigator.

Each carton of VIVITROL includes:

Items included in each carton of VIVITROL®

One – Package Insert/Directions for Use

One – Medication Guide


One – Diluent for the suspension of VIVITROL Microspheres


One – Vial containing VIVITROL Microspheres


One – Prepackaged Syringe


Two – TERUMO® 1 1/2 inch 20G Administration Needles with clear Needle Protection Device [one spare]


Two – TERUMO® 2-inch 20G Administration Needles with clear Needle Protection Device [one spare]


One – TERUMO® 1-inch 20G Preparation Needle [Not for Administration]

Parenteral products should be visually inspected for particulate matter and discoloration prior to administration.


To ensure proper dosing, it is important to follow the preparation and administration instructions.

VIVITROL must be suspended only in the diluent supplied in the carton and must be administered only with one of the administration needles supplied in the carton. The microspheres, diluent, preparation needle, and an administration needle with needle protection device are required for preparation and administration. Two thin-walled 1 1/2-inch needles with needle protection device and two 2-inch thin-walled needles with needle protection device have been provided to accommodate varying patient body habitus. For patients with a larger amount of subcutaneous tissue overlying the gluteal muscle, the administering healthcare provider may utilize the supplied 2-inch needle with needle protection device to help ensure that the injectate reaches the intramuscular mass. For very lean patients, the 1 1/2-inch needle may be appropriate to prevent the needle contacting the periosteum. Either needle may be used for patients with average body habitus. A spare administration needle of each size is provided in case of clogging. Do not substitute any other components for the components of the carton.

Prior to preparation, allow drug to reach room temperature (approximately 45 minutes).

Parenteral products should be visually inspected for particulate matter and discoloration prior to administration whenever solution and container permit. A properly mixed suspension will be milky white, will not contain clumps, and will move freely down the wall of the vial.

Keep out of reach of children.

Prepare and administer the VIVITROL suspension using aseptic technique.

  • WARNING: To reduce the risk of a needlestick:
    • Do not intentionally disengage the needle protection device.
    • Discard bent or damaged needle into a sharps container and use the spare needle provided. Do not attempt to straighten the needle or engage needle protection device if the needle is bent or damaged.
    • Do not mishandle the needle protection device in a way that could lead to protrusion of the needle.
    • Do not use free hand to press sheath over needle.


The entire carton should be stored in the refrigerator (2° to 8°C, 36° to 46°F). Unrefrigerated, VIVITROL microspheres can be stored at temperatures not exceeding 25°C (77°F) for no more than 7 days prior to administration. Do not expose unrefrigerated product to temperatures above 25°C (77°F). VIVITROL should not be frozen.

See Prescribing Information for complete directions for use.

VIVITROL is not right for everyone. There are significant risks from VIVITROL treatment, including risk of opioid overdose, injection site reactions and sudden opioid withdrawal.
See Important Safety Information below. Discuss all benefits and risks with your patients. See Prescribing Information. Review Medication Guide with your patients.

Request A Representative


Request a visit from a VIVITROL representative
to learn more about how VIVITROL may help
your patients with opioid dependence and
alcohol dependence.


VIVITROL® Co-pay Savings Program


Learn how the VIVITROL® Co-pay Savings Program may assist eligible* patients with out-of-pocket expenses for their VIVITROL prescriptions.



  1. VIVITROL [prescribing information]. Waltham, MA: Alkermes, Inc; rev March 2021.

*Terms and Conditions

Eligibility for Alkermes-Sponsored Co-pay Savings. This offer is only available to patients 18 years or older, with a prescription consistent with the Prescribing Information and the patient is not enrolled in, or covered by, any local, state, federal or other government program that pays for any portion of medication costs, including but not limited to Medicare, including Medicare Part D or Medicare Advantage plans; Medicaid, including Medicaid Managed Care and Alternative Benefit Plans under the Affordable Care Act; Medigap; VA; DOD; TRICARE; or a residential correctional program.
Additional Terms of Use: This offer is not conditioned on any past, present, or future purchase, including refills. Alkermes reserves the right to rescind, revoke, or amend this offer, program eligibility, and requirements at any time without notice. This offer is limited to one per patient, may not be used with any other offer, is not transferable and may not be sold, purchased or traded, or offered for sale, purchase or trade. Void where prohibited by law. Program Administrator or its designee will have the right upon reasonable prior written notice, during normal business hours, and subject to applicable law, to audit compliance with this program.